← ANALYST RATINGS · TIPRANKS
Fennec Pharmaceuticals (FENC): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $17.00, the highest $18.00, the lowest $16.00. The average is +70.3% from the last price of $9.98.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.50 → $11.00−4.3% | Buy | +10.2% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.50 → $10.00−4.8% | Hold | +0.2% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 → $11.00−4.3% | Buy | +10.2% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.50 → $11.00−4.3% | Buy | +10.2% | Upgrade | 17.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $11.00−4.3% | Buy | +10.2% | Upgrade | 15.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.00 → $10.50−4.5% | Hold | +5.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $16.00 | Buy | +60.3% | Reiterated | 09.09.26on TipRanks 06:55 | −6.0%next day −2.4% · 5 days −8.3% | ↗ |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $15.00 → $20.00+33.3% | Buy | +100.4% | Assigned | 13.08.26on TipRanks 11:30 | +1.2%next day −2.6% · 5 days −3.9% | ↗ |
| Unknown Analyst | Wedbush | $13.00 → $16.00+23.1% | Buy | +60.3% | Reiterated | 12.08.26on TipRanks 09:56 | −7.7%next day +1.2% · 5 days +0.8% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | $16.00 → $18.00+12.5% | Buy | +80.4% | Assigned | 12.08.26on TipRanks 09:35 | −7.7%next day +1.2% · 5 days +0.8% | ↗ |
| Unknown Analyst | B. Riley Securities | $16.00 → $18.00+12.5% | Buy | +80.4% | Initiated | 12.08.26on TipRanks 09:35 | −7.7%next day +1.2% · 5 days +0.8% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $18.00 | Buy | +80.4% | Reiterated | 15.05.26on TipRanks 07:00 | +6.7%next day −1.5% · 5 days +1.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Fennec Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $17.60 at a price of $10.65 (+65.3%); now: $17.60 at $9.98 (+76.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 5 | 2 | 1 | 1 | 1 |
| Buy | 4 | 2 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.09 (from $0.06 to $0.14). Last quarter: $0.05.
Sales
Next quarter’s sales estimate — $19M (from $18M to $20M). Last quarter: $18M.
Best top-analyst consensus in the sector · Healthcare
About Fennec Pharmaceuticals
- CEO: Jeffrey S. Hackman
- Employees: 35
- 68 TW Alexander Drive, Research Triangle Park, NC, 27709, US
- www.fennecpharma.com
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Data from the stock’s TipRanks forecast page, read 48 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗